In an 8–0 decision issued on Dec. 10, the justices ruled that states have the right to impose regulations on pharmacy benefit managers (PBMs). The ACR and its partners in the Alliance for Transparent and Affordable Prescriptions filed an amicus brief in the case highlighting the serious practical and policy consequences of PBM practices on drug costs and patient access.
The proposed payment model for Medicare Part B drugs threatens the financial solvency of rheumatology practices and severely jeopardizes our patients' access to the therapies they need. Voice your concerns today and implore the agency to work with the healthcare community to rein in drug prices without hurting patients and providers.
Marcus Snow, MD, FACR, was drawn to rheumatology by its mix of a narrow clinical focus with interesting patient cases. Fifteen years later, he is expanding his leadership in the field at the helm of the ACR’s Committee on Rheumatologic Care.
